Hamilton Fairley Award
The distinguished Hamilton Fairley Award was established in 1988 to commemorate one of the founding fathers of medical oncology in Europe. It is presented to candidates who are internationally recognised for outstanding achievements in cancer science and clinical/translational research
2015 – Cornelis Punt, Netherlands
The Hamilton Fairley Award was presented to Cornelis Punt during the European Cancer Congress 2015
Professor Cornelis Punt is a world leader in the field of gastrointestinal cancer and tumour immunology. A pioneer in the translation of immunotherapy approaches from the laboratory to the clinic, he has made a significant contribution to the development of dendritic cell vaccination. He is known as the designer and principal investigator of the Dutch Colorectal Cancer Group (DCCG) phase 3 CAIRO studies in metastatic colorectal cancer (mCRC).
Punt is highly respected for involving other disciplines in his research, sharing his data with others, and creating a network including approximately 80% of Dutch hospitals. He is currently conducting CAIRO-4 and CAIRO-5 which, in common with the previous CAIRO studies, are addressing issues that are highly relevant for clinical practice and will provide a wealth of clinical and translational research data.
I am very honoured to have been selected for this prestigious ESMO award. Given the line of my research, I consider this award as recognition of the great value of investigator-initiated clinical and translational research.
Punt has been an active ESMO member for more than 25 years and has been chairman of the ESMO Publication Committee, a member of the ESMO Educational Committee’s Faculty groups on Gastro-Intestinal Tumours; Melanoma; and Tumours Immunology and Immunotherapy. He was an associate editor of ESMO’s scientific journal, Annals of Oncology, from 1999 to 2014.
Previous winners of the Hamilton Fairley award
2014 – Heikki Joensuu, Finland
Heikki Joensuu is a member of the ESMO Faculty for Sarcoma. He is known internationally for his clinical and translational research on breast cancer and gastrointestinal stromal tumour (GIST). In 2000 Joensuu and his colleagues discovered that imatinib was effective for most advanced GISTs. In 2004 they began to research imatinib as adjuvant treatment of GIST and in 2011 found that it improved recurrence free survival and possibly overall survival. Joensuu has chaired important studies on breast cancer including the FinHer trial.
Joensuu took the International Baccalaureate examination at the United World College of the Atlantic, UK, before studying medicine at the University of Turku, Finland, where he graduated in 1981. He became a specialist in oncology and radiation therapy in 1987 and was appointed as a Lecturer in Experimental Oncology in 1988, then Lecturer in Clinical Oncology in 1990. Heikki Joensuu became Professor of Oncology at the University of Helsinki in 1994 at the age of 37, and acted as Medical Director of the Department of Oncology, Helsinki University Central Hospital from 1995 to 2009. He is currently an Academy Professor at the University of Helsinki and Research Director at the Helsinki Comprehensive Cancer Centre.
2013 – Roger Stupp, Switzerland
Prof Stupp is known worldwide for his research on malignant gliomas, head and neck as well as lung cancers. He has been the lead investigator for establishing the use of temozolomide chemotherapy in conjunction with radiotherapy in newly diagnosed glioblastoma and determining the predictive value of MGMT gene-promoter methylation. His special clinical interests include new drug development and the association of chemotherapy and radiation. His work in clinical research has contributed to an important practice change in the neurooncology filed, introducing novel chemotherapeutics after many years.
He is Professor at the University of Zurich, Switzerland, Chair and Director of the Department of Oncology of the University Hospital Zurich and the Zurich Cancer Centre. Prof Stupp has been lead investigator on several EORTC-sponsored large phase III trials and is closely involved in bringing new anti-angiogenic and biological treatments to the clinic.
2012 – Jean-Yves Blay, France
The recipient of the 2012 Hamilton Fairley Award is Professor Jean-Yves Blay, for his contribution to translational cancer research. Jean-Yves Blay is Professor of Medicine in Medical Oncology and Head of the Medical Oncology Department and the Translational Research Pole at the Centre Léon Bérard of the Université Claude Bernard in Lyon, France. He is one of Europe’s most published lead and co-authors, with more than 350 peer-reviewed papers, principally on sarcomas, GIST and immunotherapy. He writes and lectures on public health issues such as breast and prostate cancer screening programmes. He is a president of the EORTC and serves as scientific committee member of 5 cancer centres in France. He has been a reviewer for the Journal of Clinical Oncology, Blood, Cancer, Annals of Oncology, and the European Journal of Cancer.
- 2011 - Rafael Rosell, Spain
- 2010 - Bengt Glimelius, Sweden
- 2009 - T.Andrew Lister, United Kingdom
- 2008 - Yosef Yarden, Israel
- 2006 - V. Diehl, Germany
- 2004 - B.A.J. Ponder, United Kingdom
- 2002 - A. Levitzki, Israel
- 2000 - P. Borst, The Netherlands
- 1998 - T. Tursz, France
- 1996 - A. de la Chapelle, Finland
- 1994 - B. Coiffier, France
- 1992 - H.M. Pinedo, The Netherlands
- 1990 - R. Mertelsmann, Germany
- 1988 - G. Klein, Sweden
Candidates for the award are considered by the ESMO Fellowship and Award Committee of renowned cancer leaders. After careful deliberations by the committee, its recommendations are forwarded to the ESMO Executive Board for final consideration and selection.
The choice of the award winner is made on the basis of the candidate's scientific accomplishments. No regard will be given to race, gender, and nationality, religious or political views.
The award consists of a statuette and the opportunity to give a lecture at either the ESMO or the ECC Congress, free registration, free accommodation and reimbursement of travel expenses.